Article ; Online: Everolimus as a therapeutic option in refractory epilepsy in children with tuberous sclerosis: a systematic review.
2023 Volume 81, Issue 4, Page(s) 392–398
Abstract: Background: Tuberous sclerosis (TS) is a multisystem genetic disease in which epilepsy is a frequent manifestation and is often difficult to control. Everolimus is a drug with proven efficacy in the treatment of other conditions related to TS, and some ... ...
| Title translation | Everolimo como opção terapêutica na epilepsia refratária em crianças com esclerose tuberosa: uma revisão sistemática. |
|---|---|
| Abstract | Background: Tuberous sclerosis (TS) is a multisystem genetic disease in which epilepsy is a frequent manifestation and is often difficult to control. Everolimus is a drug with proven efficacy in the treatment of other conditions related to TS, and some evidence suggests that its use benefits the treatment of refractory epilepsy in these patients. Objective: To evaluate the efficacy of everolimus in controlling refractory epilepsy in children with TS. Methods: A literature review was conducted in the Pubmed, BVS, and Medline databases, using the descriptors Results: Our search screened 246 articles from electronic databases, 6 of which were chosen for review. Despite the methodological variations between the studies, most patients benefited from the use of everolimus to control refractory epilepsy, with response rates ranging from 28.6 to 100%. Adverse effects were present in all studies leading to dropouts of some patients; however, the majority were of low severity. Conclusion: The selected studies suggest a beneficial effect of everolimus in the treatment of refractory epilepsy in children with TS, despite the adverse effects observed. Further studies involving a larger sample in double-blind controlled clinical trials should be performed to provide more information and statistical credibility. |
| MeSH term(s) | Humans ; Child ; Drug Resistant Epilepsy/drug therapy ; Drug Resistant Epilepsy/etiology ; Everolimus/therapeutic use ; Prospective Studies ; Tuberous Sclerosis/complications ; Tuberous Sclerosis/drug therapy ; Combined Modality Therapy ; Drug-Related Side Effects and Adverse Reactions ; Randomized Controlled Trials as Topic |
| Chemical Substances | Everolimus (9HW64Q8G6G) |
| Language | English |
| Publishing date | 2023-03-02 |
| Publishing country | Germany |
| Document type | Systematic Review ; Journal Article |
| ZDB-ID | 418916-4 |
| ISSN | 1678-4227 ; 0004-282X |
| ISSN (online) | 1678-4227 |
| ISSN | 0004-282X |
| DOI | 10.1055/s-0042-1758442 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Ui I Zs.239: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.